Medical Device | June 30, 2022
NADMED brings first CE-marked NAD+ analysis kit to the market
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
It is a two dose vaccine to be administered intramuscularly at 28 days apart
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Tislelizumab is now approved in nine indications in China
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Subscribe To Our Newsletter & Stay Updated
